1. L Babuin,A Jaffe (2005). Troponin: the Biomarker of choice for the detection of Cardiac Injury. CMAJ, 173(10), 1191-1202.
2. M Boluyt,X Long,T Eschenhagen,U Mende,W Schmitz,M Crow,E Lakatta (1995). Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. American Journal of Physiology-Heart and Circulatory Physiology, 269(2), H638-H647.
3. S Brady,M York,C Scudamore,T Williams,W Griffiths,J Turton (2010). Cardiac troponin I in isoproterenol-induced cardiac injury in the Hanover Wistar rat: studies on low dose levels and routes of administration. ToxicolPathol, 38(2), 287-291.
4. A Burke (2011). Unknown Title. Dilated Cardiomyopathy Pathology
5. Michel Burnier (2001). Angiotensin II Type 1 Receptor Blockers. Circulation, 103(6), 904-912.
6. Yu-Si Cheng,De-Zai Dai,Yin Dai (2009). Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCε in the heart, which are mitigated by endothelin receptor antagonist CPU0213. Acta Pharmacologica Sinica, 30(8), 1099-1106.
7. D Chowdhury,A Tangutur,T Khatua,P Saxena,S Banerjee,M Bhadra (2013). A proteomic view of isoproterenol induced cardiac hypertrophy: Prohibitin identified as a potential biomarker in rats. J. Transl Med, 11(1), 1-13.
8. A Deschamps,F Spinale (2006). Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation. Cardiovascular Research, 69(3), 666-676.
9. Delisa Fairweather,Eric D.,Michael J. (2011). Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy. Myocarditis, 16, 323-348.
10. Sam Gopald (2013). New and emerging biomarkers in left ventricular systolic dysfunction-insight into dilated cardiomyopathy. J. of Cardiovasc. Trans. Res, 6, 516-527.
11. M Gray,C Long,J Kalinyak,H Li,J Karliner (1998). Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblasts. Cardiovascular Research, 40(2), 352-363.
12. D Grimm,D Elsner,H Schunkert,M Pfeifer,D Griese,G Bruckschlegel,F Muders,G Riegger,E Kromer (1998). Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res, 37(1), 91-100.
13. Pamela Harvey,Leslie Leinwand (2011). Cellular mechanisms of cardiomyopathy. Journal of Cell Biology, 194(3), 355-365.
14. L Heather,M Cole,C Lygate,R Evans,D Stuckey,A Murray,S Neubauer,K Clarke (2009). Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovascular Research, 72(3), 430-437.
15. Eugene Herman,Jun Zhang,Steven Lipshultz,Nader Rifai,Douglas Chadwick,Kazuyo Takeda,Zu-Xi Yu,Victor Ferrans (1999). Correlation Between Serum Levels of Cardiac Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by Doxorubicin. Journal of Clinical Oncology, 17(7), 2237-2237.
16. S Ichihara,T Senbonmatsu,E Price,T Ichiki,F Gaffney,T Inagami (2001). Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation, 104(3), 346-351.
17. Shokei Kim,Hiroshi Iwao (2000). Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases. Pharmacological Reviews, 52(1), 11-34.
18. H Kakuta,K Sudoh,M,Yamagishi (2005). Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res, 25(1), 41-46.
19. Lili Li,Yao Zhang,Yongli Li,Bo Yu,Yan Xu,Shidan Zhao,Zhenzhong Guan (2008). Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transplant International, 21(12), 1181-1189.
20. Barry Maron,Jeffrey Towbin,Gaetano Thiene,Charles Antzelevitch,Domenico Corrado,Donna Arnett,Arthur Moss,Christine Seidman,James Young (2006). Contemporary Definitions and Classification of the Cardiomyopathies. Circulation, 113(14), 1807-1816.
21. Charles Mccartan,Robert Mason,S Jayasinghe,Lyn Griffiths (2012). Cardiomyopathy Classification: Ongoing Debate in the Genomics Era. Biochemistry Research International, 2012, 1-10.
22. P Mehta,K Griendling (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol, 292(1), C82-C97.
23. G Montalescot,H Drexler,R Gallo,T Pearson,M Thoenes,D Bhatt (2009). Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. European Heart Journal, 30(22), 2733-2741.
24. María Ocaranza,Guillermo Díaz-Araya,Mario Chiong,David Muñoz,Juan Riveros,Roberto Ebensperger,Sebastián Sabat,Pablo Irarrázaval,Jorge Jalil,Sergio Lavandero (2002). Isoproterenol and Angiotensin I-Converting Enzyme in Lung, Left Ventricle, and Plasma During Myocardial Hypertrophy and Fibrosis. Journal of Cardiovascular Pharmacology, 40(2), 246-254.
25. A Palaniyappan,R Uwiera,H Idikio,B Jugdutt (2009). Comparison of Vasopeptidase inhibitor Omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction. Mol Cell Biochem, 321(1-2), 9-22.
26. C Richer,P Fornes,C Cazaubon,V Domergue,D Nisato,J Giudicelli (1999). Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovascular Research, 41(1), 100-108.
27. Vanessa Roldán,Francisco Marín,Juan Gimeno,Francisco Ruiz-Espejo,Josefa González,Eloisa Feliu,Antonio García-Honrubia,Daniel Saura,Gonzalo De La Morena,Mariano Valdés,Vicente Vicente (2008). Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. American Heart Journal, 156(1), 85-91.
28. Andrey Serra,Maria Higuchi,Silvia Ihara,Ednei Antônio,Marília Santos,Maria Bombig,Paulo Tucci (2008). Exercise Training Prevents β-Adrenergic Hyperactivity-Induced Myocardial Hypertrophy and Lesions. European Journal of Heart Failure, 10(6), 534-539.
29. K Shirai,K Watanabe,M Ma,M Wahed,M Inoue,Y Saito,P Suresh,T Kashimura,H Tachikawa,M Kodama,Y Aizawa (2005). Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. Mol Cell Biochem, 269(1-2), 137-142.
30. Ulka Tipnis,Gui He,Suzhen Li,Gerald Campbell,Paul Boor (2000). Attenuation of Isoproterenol-mediated Myocardial Injury in Rat by an Inhibitor of Polyamine Synthesis. Cardiovascular Pathology, 9(5), 273-280.
31. Paolo Verdecchia,Fabio Angeli,Salvatore Repaci (2009). Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag, 939-948.
32. Randy Wexler,Terry Elton,Christopher Taylor,Adam Pleister,David Feldman (2009). Physician reported perception in the treatment of high blood pressure does not correspond to practice. BMC Family Practice, 10(1), 778-784.
33. Malcolm York,Cheryl Scudamore,Sally Brady,Christabelle Chen,Sharon Wilson,Mark Curtis,Gareth Evans,William Griffiths,Matthew Whayman,Thomas Williams,John Turton (2007). Characterization of Troponin Responses in Isoproterenol-Induced Cardiac Injury in the Hanover Wistar Rat. Toxicologic Pathology, 35(4), 606-617.